Market Overview

Castle Biosciences IPO: What You Need To Know

Share:
Castle Biosciences IPO: What You Need To Know

A genomic testing company that offers predictive tools for diagnosing cancer is part of the IPO slate for the week.

The IPO Terms

Friendswood, Texas-based Castle Biosciences, Inc. proposes to offer 3.33 million shares in an IPO, according to a S-1/A filing.

The offering is expected to be priced between $14 and $16, likely raising $50 million, assuming it is priced at the mid-point of the range.

The shares of the company have been approved for listing on the Nasdaq under the ticker symbol CSTL.

SVB Leerink and Baird are the joint book-running managers for the offering, while Canaccord Genuity and BTIG are co-managers.

See Also: IPO Outlook For The Week: Biotech, Health Analytics, Sports And Solar Power

The Company

Castle is a commercial-stage dermatological cancer company that provides physicians and their patients personalized, clinically actionable genomic information to make more accurate treatment decisions.

Its non-invasive products use proprietary algorithms to provide an assessment of a patient's specific risk of metastasis or recurrence of their cancer.

Castle's lead product DecisionDx-Melanoma is a multi-gene expression profile test that predicts the risk of metastasis or recurrence for patients diagnosed with invasive cutaneous melanoma, a deadly skin cancer. It also markets DecisionDx-UM, which predicts the risk of metastasis for patients with uveal melanoma, a rare eye cancer. Both the tests have Medicare coverage.

The company has two late-stage proprietary product candidates that are being developed for predicting cutaneous squamous cell carcinoma and suspicious pigmented lesions.

The Finances

Castle's fiscal year 2018 revenues increased year-year-year from $13.75 million to $22.79 million and its net loss narrowed from $15.31 million to $10.16 million.

For the three months ended March 31, the company reported net revenues of $8.72 million, up 138% year-over-year. The net loss narrowed from $4.49 million to $2.34 million.

Posted-In: Biotech News Previews IPOs Top Stories Trading Ideas General Best of Benzinga

 

Related Articles (CSTL)

View Comments and Join the Discussion!
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com